MD3119B2 - Forma medicamentoasa pentru administrare orala cu eliberarea prelungita a molsidominei - Google Patents

Forma medicamentoasa pentru administrare orala cu eliberarea prelungita a molsidominei

Info

Publication number
MD3119B2
MD3119B2 MDA20020212A MD20020212A MD3119B2 MD 3119 B2 MD3119 B2 MD 3119B2 MD A20020212 A MDA20020212 A MD A20020212A MD 20020212 A MD20020212 A MD 20020212A MD 3119 B2 MD3119 B2 MD 3119B2
Authority
MD
Moldova
Prior art keywords
hours
released
molsidomine
prolonged release
drug form
Prior art date
Application number
MDA20020212A
Other languages
English (en)
Other versions
MD20020212A (ro
MD3119C2 (ro
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Limited filed Critical Therabel Pharmaceuticals Limited
Publication of MD20020212A publication Critical patent/MD20020212A/ro
Publication of MD3119B2 publication Critical patent/MD3119B2/ro
Publication of MD3119C2 publication Critical patent/MD3119C2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Inventia se refera la o forma medicamentoasa pentru administrare orala cu eliberare prelungita a molsidominei si poate fi utilizata in tratamentul tuturor formelor de stenocardie (stenocardie de efort sau de repaus, stare de preinfarct). Esenta inventiei consta in aceea ca forma medicamentoasa contine o cantitate terapeutic eficienta de molsidomina sau unul din metabolitii sai activi, selectatdintre SIN-1 si SIN-1A, avand un indice de dizolvare in vitro [masurat spectrofotometric la 286 sau 311 nm dupa metoda descrisa in European Pharmacopeia, editia a 3-a (sau USP XXIV), la 50 rot./min, in 500 ml de 0,1 N HCl, la 37°C] de: 15...25% demolsidomina eliberata dupa 1 ora, 20...35% eliberata dupa 2 ore, 50...65% de eliberata dupa 6 ore,75...95% eliberata dupa 12 ore, mai mult de 85% eliberata dupa 18 ore si mai mult de 90% de molsidomina eliberata dupa 24 ore, concentratia maxima demolsidomina in plasma in vivo, si anume de 25...40 ng/ml se obtine de la 2,5 la 5 ore, preferabil de la 3 la 4 ore dupa administrarea formei mentionate.
MDA20020212A 2000-02-24 2001-02-22 Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei MD3119C2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002307A FR2805462B1 (fr) 2000-02-24 2000-02-24 Nouvelle forme galenique orale a liberation prolongee de la molsidomine
PCT/EP2001/002055 WO2001062256A1 (fr) 2000-02-24 2001-02-22 Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Publications (3)

Publication Number Publication Date
MD20020212A MD20020212A (ro) 2002-12-31
MD3119B2 true MD3119B2 (ro) 2006-08-31
MD3119C2 MD3119C2 (ro) 2007-04-30

Family

ID=8847342

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20020212A MD3119C2 (ro) 2000-02-24 2001-02-22 Formă medicamentoasă pentru administrare orală cu eliberarea prelungită a molsidominei

Country Status (36)

Country Link
US (1) US7767227B2 (ro)
EP (1) EP1265614B1 (ro)
JP (1) JP4945043B2 (ro)
KR (1) KR100814191B1 (ro)
CN (1) CN100396284C (ro)
AT (1) ATE296632T1 (ro)
AU (2) AU2001240653B9 (ro)
BE (1) BE1013487A3 (ro)
BG (1) BG66111B1 (ro)
BR (1) BRPI0108041B8 (ro)
CA (1) CA2400886C (ro)
CZ (1) CZ301993B6 (ro)
DE (1) DE60111196T2 (ro)
DZ (1) DZ3273A1 (ro)
EE (1) EE05098B1 (ro)
ES (1) ES2241803T3 (ro)
FR (1) FR2805462B1 (ro)
HK (1) HK1050138B (ro)
HR (1) HRP20020692B1 (ro)
HU (1) HU229799B1 (ro)
IL (2) IL151205A0 (ro)
IS (1) IS2446B (ro)
MA (1) MA25576A1 (ro)
MD (1) MD3119C2 (ro)
MX (1) MXPA02008262A (ro)
NO (1) NO329495B1 (ro)
NZ (1) NZ520691A (ro)
OA (1) OA12183A (ro)
PL (1) PL201631B1 (ro)
PT (1) PT1265614E (ro)
RS (1) RS50291B (ro)
RU (1) RU2263506C2 (ro)
SK (1) SK286313B6 (ro)
UA (1) UA73972C2 (ro)
WO (1) WO2001062256A1 (ro)
ZA (1) ZA200206042B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2868314B1 (fr) 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
EP2468269A1 (en) 2010-11-26 2012-06-27 Universitätsklinikum Münster Nitric oxide donors in therapy of nitric oxide deficiency-induced disturbances of cerebral microcirculation
BE1028879B1 (fr) 2020-12-11 2022-07-12 Europharmaceuticals Comprimé à libération prolongée de la molsidomine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522191A1 (de) * 1985-06-21 1987-01-15 Cassella Ag Photostabilisierung von sydnoniminen
CN1006522B (zh) * 1986-04-30 1990-01-24 田道制药有限公司 缓放性制剂的制备方法
HU211648A9 (en) * 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) * 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ES2139032T3 (es) * 1993-05-11 2000-02-01 Hoechst Ag Composiciones galenicas a base de molsidomina.
JPH09503997A (ja) * 1993-07-08 1997-04-22 シグナス,インコーポレイテッド モノリシックなマトリックス経皮送達システム
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
HU218280B (en) * 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
DE4443105C2 (de) * 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
JPH09114680A (ja) * 1995-10-19 1997-05-02 Fuji Xerox Co Ltd シーケンス制御装置
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6692767B2 (en) * 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine

Also Published As

Publication number Publication date
FR2805462A1 (fr) 2001-08-31
HK1050138B (zh) 2005-07-29
SK12202002A3 (sk) 2002-12-03
YU62202A (sh) 2006-01-16
FR2805462B1 (fr) 2003-08-15
NO329495B1 (no) 2010-11-01
KR20020081323A (ko) 2002-10-26
RS50291B (sr) 2009-09-08
JP4945043B2 (ja) 2012-06-06
HRP20020692B1 (en) 2011-10-31
EE05098B1 (et) 2008-12-15
AU2001240653B9 (en) 2005-10-27
BE1013487A3 (fr) 2002-02-05
HK1050138A1 (en) 2003-06-13
NO20024043L (no) 2002-08-23
US20030045522A1 (en) 2003-03-06
PL201631B1 (pl) 2009-04-30
HRP20020692A2 (en) 2004-02-29
PL357550A1 (en) 2004-07-26
BR0108041A (pt) 2002-10-29
BG66111B1 (bg) 2011-05-31
DZ3273A1 (fr) 2001-08-30
MD20020212A (ro) 2002-12-31
IL151205A0 (en) 2003-04-10
ES2241803T3 (es) 2005-11-01
BRPI0108041B8 (pt) 2021-05-25
AU4065301A (en) 2001-09-03
OA12183A (fr) 2006-05-09
IS6504A (is) 2002-08-14
IL151205A (en) 2011-01-31
HU229799B1 (en) 2014-07-28
ZA200206042B (en) 2003-07-29
NZ520691A (en) 2004-07-30
CA2400886A1 (fr) 2001-08-30
AU2001240653B2 (en) 2005-05-26
BR0108041B1 (pt) 2013-06-18
MA25576A1 (fr) 2002-10-01
CZ301993B6 (cs) 2010-09-01
WO2001062256A1 (fr) 2001-08-30
CN1419451A (zh) 2003-05-21
HUP0300607A3 (en) 2006-02-28
KR100814191B1 (ko) 2008-03-17
MD3119C2 (ro) 2007-04-30
SK286313B6 (en) 2008-07-07
PT1265614E (pt) 2005-10-31
JP2003523981A (ja) 2003-08-12
EP1265614A1 (fr) 2002-12-18
DE60111196D1 (de) 2005-07-07
EE200200472A (et) 2003-12-15
NO20024043D0 (no) 2002-08-23
CA2400886C (fr) 2011-04-19
BG107027A (bg) 2003-04-30
HUP0300607A2 (hu) 2003-08-28
UA73972C2 (en) 2005-10-17
RU2263506C2 (ru) 2005-11-10
IS2446B (is) 2008-11-15
DE60111196T2 (de) 2006-05-11
EP1265614B1 (fr) 2005-06-01
US7767227B2 (en) 2010-08-03
ATE296632T1 (de) 2005-06-15
RU2002121503A (ru) 2004-03-20
CN100396284C (zh) 2008-06-25
MXPA02008262A (es) 2004-04-05

Similar Documents

Publication Publication Date Title
HUP0302897A2 (hu) Kiváló hatású transzdermális terápiás készítmény a Parkinson-kór kezelésére
HUP0001382A2 (hu) Eritromicinszármazékokat tartalmazó, ezek késleltetett felszabadulását biztosító készítmények
HUP0201907A2 (hu) Időzített kettős hatóanyag-leadású dózisformák, amelyek rövid ideig ható altatót vagy annak sóját tartalmazzák
RS50593B (sr) Oktenidinske pastile protiv bolesti zapaljenja usta i ždrela
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
HUP0301244A2 (hu) Rapamicinvegyület alkalmazása szív-és érrendszeri megbetegedések kezelésére szánt gyógyászati készítmény előállítására
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
DE60123100D1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
DE50112452D1 (de) Transdermales therapeutisches system zur behandlung des restless-legs-syndroms
HUP0402421A2 (hu) Mátrix-metalloproteinázokat gátló készítmény neopláziás betegségek kezelésére
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
ITUB20152695A1 (it) Composizione per l'aumento delle secrezioni umorali
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
MD3119B2 (ro) Forma medicamentoasa pentru administrare orala cu eliberarea prelungita a molsidominei
NO20013414L (no) Ny anvendelse av melagatran
MA28036A1 (fr) Utilisation d'oxcarbazepine dans le traitement de la douleur liee a la neuropathie diabetique et dans l'amelioration du sommeil
SE0102887D0 (sv) New formulation
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
WO2003101462A3 (en) Use of bisphosphonic acid derivatives for the treatment of calcium phrophosphated deposition disease and dental treatment
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
RU2006134695A (ru) Пероральная композиция с пролонгированным высвобождением молсидомина для лечения атеросклероза
Hermida et al. P-205: Administration time-dependent effects on ambulatory blood pressure of doxazosin gits as added therapy in uncontrolled hypertensive patients

Legal Events

Date Code Title Description
FG4A Patent for invention issued